PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

623 articles indexed across 24 specialties, each reviewed by a licensed pharmacist before publication.

Showing 67 from 1 topic.Sort: Newest | Oldest
PID versus MPC Algorithm Response to Unannounced Meals in Adolescents
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low

The PID algorithm optimizes glycemic control for unannounced meals in adolescents with type 1 diabetes.

Setmelanotide Cuts BMI 19.8 Points Versus Placebo in Hypothalamic Obesity
Analysis Endocrinology / Diabetes / Obesity Practice-changing Grade: Moderate
Also in Pediatrics

Setmelanotide shows promise in reducing BMI in hypothalamic obesity.

Intensive Glucose Targets: No Mortality Gain, 3.6-Fold Hypoglycemia Risk
Analysis Critical Care / ICU Confirmatory Grade: Moderate
Also in Endocrinology / Diabetes / Obesity

Intensive glycemic control cuts morbidity but triples hypoglycemia risk.

Semaglutide cuts heavy drinking in alcohol use disorder with obesity
Analysis Behavioral Health / Addiction Medicine Hypothesis-generating Grade: Moderate
Also in Endocrinology / Diabetes / Obesity

Semaglutide reduces alcohol intake in comorbid obesity.

Semaglutide Cuts Cardiovascular Events in Obesity Without Diabetes
Analysis Endocrinology / Diabetes / Obesity Practice-changing Grade: High
Also in Cardiology

Semaglutide cuts heart risks in obesity without diabetes.

Semaglutide Cuts Symptoms and Weight in Obesity-Related HFpEF
Analysis Endocrinology / Diabetes / Obesity Practice-changing Grade: High
Also in Cardiology

Semaglutide enhances function and weight loss in obese heart failure patients.

Tirzepatide Delivers Up to 21% Weight Loss in Obesity
Analysis Endocrinology / Diabetes / Obesity Practice-changing Grade: High

Tirzepatide delivers unprecedented weight loss results in obesity management.